Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug interactions with tacrolimus.

Teun van Gelder1

  • 1Department of Internal Medicine, University Hospital Rotterdam--Dijkzigt, Rotterdam, The Netherlands. vangelder@INW1.AZR.NL

Drug Safety
|August 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Neurology·2026
Same author

Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Neurology·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026
Same author

ESCP best practice: development, implementation and evaluation of sick day guidance in primary care in the Netherlands.

International journal of clinical pharmacy·2026
Same author

Current Practice of Palliative Sedation in Dutch Nursing Homes.

Journal of the American Medical Directors Association·2026
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

Therapeutic drug monitoring of tacrolimus is crucial due to numerous drug interactions. Understanding how drugs like corticosteroids affect tacrolimus levels prevents toxicity or rejection in transplant patients.

Area of Science:

  • Pharmacology
  • Transplantation Medicine
  • Drug Metabolism

Background:

  • Tacrolimus therapy requires monitoring due to significant drug interaction potential.
  • Cytochrome P450 (CYP)3A and P-glycoprotein in the gut influence tacrolimus oral bioavailability.
  • Liver CYP activity also impacts tacrolimus concentrations.

Purpose of the Study:

  • To highlight the importance of therapeutic drug monitoring for tacrolimus.
  • To explain the mechanisms of drug interactions affecting tacrolimus.
  • To emphasize the clinical significance of managing these interactions.

Main Methods:

  • Review of tacrolimus pharmacokinetics and drug metabolism pathways.
  • Analysis of known drug interactions involving CYP3A and P-glycoprotein.

Related Experiment Videos

  • Discussion of clinical implications of altered tacrolimus levels.

    • Main Results:

    • Concomitant use of CYP3A or P-glycoprotein inhibitors can increase tacrolimus bioavailability.
    • Drugs like corticosteroids and antifungals frequently used in transplantation interact with tacrolimus.
    • These interactions can lead to significant under- or overexposure to tacrolimus.

    Conclusions:

    • Therapeutic drug monitoring of whole blood tacrolimus concentrations is essential.
    • Awareness of drug interactions is critical for preventing adverse outcomes like acute rejection or toxicity.
    • Effective management of tacrolimus therapy relies on understanding its metabolic pathways and interactions.